Cantargia has carried out a preferential rights issue of approximately SEK 250 million. 

Cantargia is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Barclays and Carnegie acted as Joint Global Coordinators and Bookrunners. Baker McKenzie acted as legal advisor to Barclays and Carnegie with an international capital markets team consisting of Joakim Falkner and Johanna Flink from Stockholm, James Thompson, Luke Hackett and Reema AlSalem in London as to English law as well as Adam Farlow and Charles Farnsworth in London as to US law.

Explore Our Newsroom